Tenaya Therapeutics reported a net loss of $43.4 million for the quarter ended June 30, 2026, compared to a $23.3 million loss in the prior year period. The increase was primarily driven by a $21.8 million non-cash impairment charge related to the early termination of its Union City Genetic Medicines Manufacturing Center lease. Cash and cash equivalents stood at $78.1 million as of June 30, 2026, including a $10.0 million upfront payment received from Alnylam in April 2026 under their collaboration agreement. The company expects its existing cash runway to extend through the third quarter of 2027. Clinically, Tenaya shared positive interim data for TN-201 and TN-401 gene therapies, noting improvements in disease characteristics and safety profiles. The company plans to provide updates on regulatory discussions for pivotal trials in Q4 2026 and anticipates advancing TN-301 toward Phase 2 clinical trials in the second half of 2027. Tenaya Therapeutics is a clinical-stage biotechnology company focused on discovering and developing gene therapies and small molecules to treat heart disease.

Tenaya Therapeutics, Inc. entered into a Lease Termination Agreement with Terreno Park Union City LLC to terminate its lease for the 94,046 square foot Genetic Medicines Manufacturing Center in Union City, California, effective August 31, 2026. To terminate the lease early, the company will forfeit its $1,750,000 security deposit and pay a one-time fee of approximately $294,200. The company plans to transfer its AAV manufacturing process to a contract development manufacturing organization. Tenaya Therapeutics, Inc. is a biotechnology company focused on developing genetic medicines for serious diseases.